

Table S6. Additional proteins of interest.

<u>Protein (Gene)</u>	<u>Placebo</u>	<u>Calcium</u>	<u>Aquamin</u>	<u>Calcium</u> <u>(Compared to Placebo)</u>	<u>Aquamin</u> <u>(Compared to Placebo)</u>
<u>Apoptosis-related</u>					
CARD16	0.74	0.80	1.53	1.07	2.06
BIRC6	0.90	0.96	1.65	1.07	1.83
IRF3	0.78	1.20	1.40	1.53	1.78
PPM1F	0.86	1.18	1.44	1.37	1.67
CYLD	0.93	1.20	1.49	1.29	1.59
CASP14	0.68	0.31	1.09	0.45	1.59
MIEN1	0.89	0.91	1.29	1.02	1.45
BAD	0.86	0.89	1.23	1.04	1.43
RTN3	0.91	0.94	1.30	1.03	1.43
PAWR	0.89	1.05	1.25	1.18	1.40
MAP3K7	0.76	0.96	1.06	1.26	1.40
MRPL41	0.90	0.93	1.24	1.03	1.38
NOL3	0.94	1.00	1.29	1.06	1.36
BID	0.95	0.89	1.27	0.94	1.33
<u>Calcium metabolism-related</u>					
CAPN14	0.48	0.74	1.75	1.54	3.64
PKIG	0.68	0.76	1.49	1.12	2.20
CRACR2A	0.78	0.94	1.37	1.20	1.75
PPP3CB	0.94	0.92	1.36	0.98	1.45
MCUR1	0.94	0.90	1.25	0.96	1.33
CPPED1	0.94	0.99	1.21	1.05	1.29
ATP2B4	0.95	1.06	1.19	1.12	1.25
CALCOCO2	0.95	1.30	1.13	1.37	1.20

The values represent fold-change of abundance ratio as compared to the control (all baseline samples and post-intervention placebo samples). These samples were assessed by TMT based differential proteomic expression by pooling the samples for each group. Protein FDR Confidence for all the proteins was $\leq 2\%$.